Literature DB >> 10073857

Determinants of pulmonary venous flow reversal in mitral regurgitation and its usefulness in determining the severity of regurgitation.

M Enriquez-Sarano1, K S Dujardin, C M Tribouilloy, J B Seward, A P Yoganathan, K R Bailey, A J Tajik.   

Abstract

Pulmonary venous flow (PVF) reversal is observed in mitral regurgitation (MR) and can be detected by Doppler echocardiography. However, the determinants of PVF alterations in MR have not been analyzed with simultaneous quantitative methods, and the diagnostic accuracy of flow reversal is uncertain. Prospectively, in 128 patients with isolated MR of various degrees (regurgitant fraction 4% to 81%), Doppler echocardiography was used to measure PVF velocity simultaneously to quantify MR by 2 methods and to perform a comprehensive hemodynamic assessment. Systolic PVF velocity was 4 +/- 56 cm/s (systolic flow reversal in 39 patients) and showed the strongest correlations with mitral effective regurgitant orifice (r = -0.56, p <0.0001). In multivariate analysis, larger effective regurgitant orifice (p <0.0001), eccentric jets (p = 0.0023), longer jets (p = 0.0033), and lower mitral regurgitant velocity (p = 0.0015) were independent determinants of decreased systolic PVF velocity. In organic MR, increased filling pressures were associated with systolic PVF reversal. Blunted systolic flow was associated with shorter mitral deceleration time (p <0.0001) and enlarged left atrium (p = 0.0007). For the diagnosis of severe MR (regurgitant orifice > or = 35 mm2, regurgitant fraction > or = 50%), systolic flow reversal sensitivity was 61% and 60%, and specificity was 92% and 85%, respectively. Among 29 patients in whom surgery demonstrated severe mitral lesions, 12 (41%) had no systolic flow reversal preoperatively. In patients with MR, the determinants of systolic PVF are complex and, in addition to the degree of MR, include the hemodynamic consequences of MR, jet characteristics, left ventricular filling, and left atrial volume alterations. Consequently, systolic PVF reversal is a useful sign of severe MR but of relatively low sensitivity, emphasizing the importance of quantifying MR.

Entities:  

Mesh:

Year:  1999        PMID: 10073857     DOI: 10.1016/s0002-9149(98)00909-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Quantitative assessment of mitral insufficiency: its advantages and disadvantages.

Authors:  Anna Paszczuk; Susan E Wiegers
Journal:  Heart Fail Rev       Date:  2006-09       Impact factor: 4.214

2.  Routine cine-CMR for prosthesis-associated mitral regurgitation: a multicenter comparison to echocardiography.

Authors:  Lauren A Simprini; Anika Afroz; Mitchell A Cooper; Igor Klem; Christoph Jensen; Raymond J Kim; Monvadi B Srichai; John F Heitner; Michael Sood; Elizabeth Chandy; Dipan J Shah; Juan Lopez-Mattei; Robert W Biederman; John D Grizzard; Anthon Fuisz; Kambiz Ghafourian; Afshin Farzaneh-Far; Jonathan Weinsaft
Journal:  J Heart Valve Dis       Date:  2014-09

Review 3.  Practical Echocardiographic Approach of the Regurgitant Mitral Valve Assessment.

Authors:  Rebeca Muñoz-Rodríguez; María Amelia Duque-González; Aida Tindaya Igareta-Herraiz; Mauro Di Silvestre; María Manuela Izquierdo-Gómez; Flor Baeza-Garzón; Antonio Barragán-Acea; Francisco Bosa-Ojeda; Juan Lacalzada-Almeida
Journal:  Diagnostics (Basel)       Date:  2022-07-15

Review 4.  Disproportionate mitral regurgitation: another myth? A critical appraisal of echocardiographic assessment of functional mitral regurgitation.

Authors:  Andreas Hagendorff; Fabian Knebel; Andreas Helfen; Stephan Stöbe; Torsten Doenst; Volkmar Falk
Journal:  Int J Cardiovasc Imaging       Date:  2020-08-26       Impact factor: 2.357

Review 5.  Echocardiographic assessment of mitral regurgitation: discussion of practical and methodologic aspects of severity quantification to improve diagnostic conclusiveness.

Authors:  Andreas Hagendorff; Fabian Knebel; Andreas Helfen; Stephan Stöbe; Dariush Haghi; Tobias Ruf; Daniel Lavall; Jan Knierim; Ertunc Altiok; Roland Brandt; Nicolas Merke; Sebastian Ewen
Journal:  Clin Res Cardiol       Date:  2021-04-11       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.